Biogen Announces Leadership Update
01 oct. 2019 08h00 HE
|
Biogen Inc.
Dr. Alfred Sandrock is named Executive Vice President, Research and Development and continues as Chief Medical Officer Dr. Alphonse Galdes appointed Executive Vice President, Pharmaceutical...
Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index
17 sept. 2019 07h30 HE
|
Biogen Inc.
CAMBRIDGE, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that it has been ranked the #1 biotechnology company on the Dow Jones Sustainability World Index (DJSI...
Biogen to Present New Safety and Efficacy Data on Biosimilars and Estimates 1.8 Billion Euros in Savings for the European Healthcare System in 2019
11 juin 2019 19h05 HE
|
Biogen Inc.
Data to be presented at the European Congress of Rheumatology (EULAR) 2019 highlight real-world evidence confirming the safety and efficacy of anti-TNF biosimilars and high adherence of patients to...
Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million
07 juin 2019 05h41 HE
|
Biogen Inc.
CAMBRIDGE, Mass., June 07, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced that it has completed its acquisition of Nightstar Therapeutics (NST; Nasdaq: NITE), a clinical-stage gene...
Biogen Recommends Stockholders Reject the Below-market Mini-tender Offer by TRC Capital Corporation
20 mai 2019 07h30 HE
|
Biogen Inc.
CAMBRIDGE, Mass., May 20, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Corporation (TRC Capital)...
Biogen to Present New Interim Data from Its Phase 1/2 Clinical Study of Tofersen (BIIB067) for the Potential Treatment of a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS)
01 mai 2019 16h30 HE
|
Biogen Inc.
Tofersen, an antisense oligonucleotide (ASO) that selectively targets the genetic driver of disease, is being studied for the potential treatment of ALS in adults with a confirmed superoxide dismutase...
Biogen To Present Data At AAN Highlighting Its Innovative Marketed Treatments And Investigational Pipeline Programs For Complex Neurodegenerative Diseases
01 mai 2019 07h30 HE
|
Biogen Inc.
Data demonstrate that pre-symptomatic infants with SMA treated with SPINRAZA® (nusinersen) over three years achieved motor milestones that are more consistent with normal childhood...
Biogen Announces Three New Nominees for Election to Board of Directors
29 avr. 2019 07h30 HE
|
Biogen Inc.
CAMBRIDGE, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced the nomination of John R. Chiminski, William A. Hawkins and Jesus B. Mantas to stand for election to the...
Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease
21 mars 2019 07h00 HE
|
Biogen Inc.
CAMBRIDGE, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced the decision to discontinue the global Phase 3 trials, ENGAGE and...
Biogen Responds to CADTH’s updated recommendation regarding coverage for SPINRAZA
01 mars 2019 20h18 HE
|
Biogen Canada
·Canadian Association of Drugs and Technologies in Health (CADTH) has expanded their recommendations for public reimbursement for SMA patients ·The recommendation, however, continues to limit access...